Latest Insider Transactions at Meridian Bioscience Inc (VIVO)
This section provides a real-time view of insider transactions for Meridian Bioscience Inc (VIVO). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of MERIDIAN BIOSCIENCE INC to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of MERIDIAN BIOSCIENCE INC's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 31
2023
|
John Mc Cune Rice Jr. Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
27,449
-100.0%
|
-
|
|
Jan 31
2023
|
Catherine Sazdanoff Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
16,424
-100.0%
|
-
|
|
Jan 31
2023
|
Felicia Williams Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
10,274
-100.0%
|
-
|
|
Jan 31
2023
|
James M. Anderson Director |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
5,000
-100.0%
|
-
|
|
Jan 31
2023
|
James M. Anderson Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
28,224
-100.0%
|
-
|
|
Jan 31
2023
|
Anthony P Bihl Iii Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
15,408
-100.0%
|
-
|
|
Jan 31
2023
|
Dwight E Ellingwood Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
17,290
-100.0%
|
-
|
|
Jan 31
2023
|
John Mc Ilwraith Director |
SELL
Sale (or disposition) back to the issuer
|
Direct |
21,724
-100.0%
|
-
|
|
Jan 31
2023
|
Tony Serafini Lamanna Executive VP-Diagnostics |
SELL
Sale (or disposition) back to the issuer
|
Direct |
43,338
-100.0%
|
-
|
|
Jan 31
2023
|
Tony Serafini Lamanna Executive VP-Diagnostics |
BUY
Grant, award, or other acquisition
|
Direct |
7,945
+15.49%
|
-
|
|
Jan 31
2023
|
Lourdes Weltzien Executive VP, Life Science |
SELL
Sale (or disposition) back to the issuer
|
Direct |
86,045
-100.0%
|
-
|
|
Jan 31
2023
|
Lourdes Weltzien Executive VP, Life Science |
BUY
Grant, award, or other acquisition
|
Direct |
7,945
+8.45%
|
-
|
|
Jan 31
2023
|
Andrew S. Kitzmiller Executive Vice President & CFO |
SELL
Sale (or disposition) back to the issuer
|
Direct |
19,473
-100.0%
|
-
|
|
Jan 31
2023
|
Andrew S. Kitzmiller Executive Vice President & CFO |
BUY
Grant, award, or other acquisition
|
Direct |
7,945
+28.98%
|
-
|
|
Jan 31
2023
|
John P. Kenny Chief Executive Officer |
SELL
Sale (or disposition) back to the issuer
|
Direct |
267,651
-100.0%
|
-
|
|
Jan 31
2023
|
John P. Kenny Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
47,060
+14.95%
|
-
|
|
Jan 31
2023
|
Julie Diana Smith Sr VP, Controller, PAO |
SELL
Sale (or disposition) back to the issuer
|
Indirect |
25,600
-100.0%
|
-
|
|
Jan 31
2023
|
Julie Diana Smith Sr VP, Controller, PAO |
SELL
Sale (or disposition) back to the issuer
|
Direct |
32,708
-100.0%
|
-
|
|
Jan 31
2023
|
Julie Diana Smith Sr VP, Controller, PAO |
BUY
Grant, award, or other acquisition
|
Direct |
2,648
+7.49%
|
-
|
|
Jan 06
2023
|
James M. Anderson Director |
BUY
Exercise of conversion of derivative security
|
Direct |
8,500
+23.15%
|
$170,000
$20.38 P/Share
|
|
Dec 06
2022
|
Julie Diana Smith Sr VP, Controller, PAO |
SELL
Payment of exercise price or tax liability
|
Direct |
374
-1.23%
|
$11,594
$31.71 P/Share
|
|
Nov 15
2022
|
Lourdes Weltzien Executive VP, Life Science |
SELL
Payment of exercise price or tax liability
|
Direct |
4,382
-5.31%
|
$135,842
$31.83 P/Share
|
|
Nov 15
2022
|
Tony Serafini Lamanna Executive VP-Diagnostics |
SELL
Payment of exercise price or tax liability
|
Direct |
3,666
-9.39%
|
$113,646
$31.83 P/Share
|
|
Nov 15
2022
|
Julie Diana Smith Sr VP, Controller, PAO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,845
-5.72%
|
$57,195
$31.83 P/Share
|
|
Nov 04
2022
|
Lourdes Weltzien Executive VP, Life Science |
SELL
Payment of exercise price or tax liability
|
Direct |
566
-0.68%
|
$18,112
$32.01 P/Share
|
|
Nov 04
2022
|
Julie Diana Smith Sr VP, Controller, PAO |
SELL
Payment of exercise price or tax liability
|
Direct |
397
-1.22%
|
$12,704
$32.01 P/Share
|
|
Nov 04
2022
|
John P. Kenny Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
4,271
-1.9%
|
$136,672
$32.01 P/Share
|
|
Nov 04
2022
|
Tony Serafini Lamanna Executive VP-Diagnostics |
SELL
Payment of exercise price or tax liability
|
Direct |
788
-1.98%
|
$25,216
$32.01 P/Share
|
|
Oct 03
2022
|
John P. Kenny Chief Executive Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
40,269
-15.19%
|
$1,248,339
$31.53 P/Share
|
|
Sep 16
2022
|
Julie Diana Smith Sr VP, Controller, PAO |
SELL
Payment of exercise price or tax liability
|
Direct |
360
-1.09%
|
$11,520
$32.14 P/Share
|
|
Sep 16
2022
|
Tony Serafini Lamanna Executive VP-Diagnostics |
SELL
Payment of exercise price or tax liability
|
Direct |
357
-0.89%
|
$11,424
$32.14 P/Share
|
|
Jun 27
2022
|
John P. Kenny Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
61,437
-18.81%
|
$1,843,110
$30.39 P/Share
|
|
Jun 27
2022
|
John P. Kenny Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
61,437
+15.83%
|
$614,370
$10.1 P/Share
|
|
Jun 24
2022
|
John P. Kenny Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
13,559
-4.87%
|
$406,770
$30.0 P/Share
|
|
Jun 24
2022
|
John P. Kenny Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
13,559
+4.64%
|
$135,590
$10.1 P/Share
|
|
Jun 23
2022
|
John P. Kenny Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
19,956
-7.0%
|
$578,724
$29.98 P/Share
|
|
Jun 23
2022
|
John P. Kenny Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
19,956
+3.41%
|
$239,472
$12.3 P/Share
|
|
Jun 22
2022
|
John P. Kenny Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
44,651
-14.41%
|
$1,294,879
$29.72 P/Share
|
|
Jun 22
2022
|
John P. Kenny Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
44,651
+12.6%
|
$625,114
$14.5 P/Share
|
|
Feb 25
2022
|
Andrew S. Kitzmiller Executive Vice President & CFO |
BUY
Open market or private purchase
|
Direct |
4,028
+25.89%
|
$96,672
$24.87 P/Share
|
|
Feb 21
2022
|
Andrew S. Kitzmiller Executive Vice President & CFO |
BUY
Grant, award, or other acquisition
|
Direct |
7,500
+50.0%
|
-
|
|
Feb 15
2022
|
Lourdes Weltzien Executive VP, Life Science |
SELL
Open market or private sale
|
Direct |
20,000
-19.41%
|
$500,000
$25.6 P/Share
|
|
Feb 15
2022
|
Lourdes Weltzien Executive VP, Life Science |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+9.18%
|
$280,000
$14.48 P/Share
|
|
Jan 26
2022
|
James M. Anderson Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,012
+13.25%
|
-
|
|
Jan 26
2022
|
Anthony P Bihl Iii Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,012
+16.35%
|
-
|
|
Jan 26
2022
|
Dwight E Ellingwood Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,012
+14.84%
|
-
|
|
Jan 26
2022
|
John Mc Ilwraith Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,012
+12.18%
|
-
|
|
Jan 26
2022
|
John Mc Cune Rice Jr. Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,012
+9.89%
|
-
|
|
Jan 26
2022
|
Catherine Sazdanoff Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,012
+15.5%
|
-
|
|
Jan 26
2022
|
Felicia Williams Director |
BUY
Grant, award, or other acquisition
|
Direct |
3,012
+22.67%
|
-
|